When should adjuvant chemotherapy be offered to patients with soft tissue sarcoma of the extremity?

The disclaimer is, this continues to be an area of debate and discussion. Having said that, the best I can do in this forum/format:

Good PS, normal organ function, high-risk STS (stage 3), extremity/superficial trunk location, excluding low/non-responsive histologies (e.g. CSS, ASPS, SFT...) should ...

This is a complex question without a singular answer.

I would suggest taking a look at the more recent neoadjuvant publications including the one below